PedAM
Pediatric Disease Annotations & Medicines
| Disease | renal cell carcinoma |
| Phenotype | C0220650|brain metastases |
| Sentences | 5 |
| PubMedID- 23265925 | Background: the effectiveness of tyrosine kinase inhibitors (tki) in preventing brain metastases in patients with renal cell carcinoma is unclear. |
| PubMedID- 25847631 | Aims: brain metastases (bms) of clear cell renal cell carcinoma (ccrcc) are associated with a dismal prognosis, with limited treatment options. |
| PubMedID- 22441343 | Objective: to assess the response of brain metastases to sunitinib in patients with renal cell carcinoma (rcc) who did not undergo prior surgical resection or radiation to the brain. |
| PubMedID- 22931379 | renal cell carcinoma patients with brain metastases have a reported mean survival time of three months if left untreated, and with treatment of wbrt the median survival time ranges from two to nine months [12,18-20]. |
| PubMedID- 20862748 | Sunitinib in metastatic renal cell carcinoma patients with brain metastases. |
Page: 1